In addition, we assessed the associations between TIGIT/CD155 levels and a set of chosen 48 cytokines, chemokines, and growth factors measured in tumor tissue to clarify how this checkpoint axis is integrated into the CRC TME and to identify potential biomarkers to support personalized immunotherapeutic strategies. The gene discussed is PVR; the disease is colorectal carcinoma.